Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.64 BRL | +0.23% | +2.15% | -12.79% |
03-06 | Transcript : Raia Drogasil S.A., Q4 2023 Earnings Call, Mar 06, 2024 | |
03-05 | Raia Drogasil S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 51% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With an expected P/E ratio at 30.42 and 22.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.79% | 8.47B | B | ||
+39.05% | 1.36B | - | ||
+8.27% | 425M | - | ||
-2.22% | 258M | - | ||
+10.56% | 224M | - | - | |
-7.34% | 84.68M | - | - | |
-47.35% | 80.77M | C | ||
+23.75% | 60.88M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RADL3 Stock
- Ratings Raia Drogasil S.A.